STERIS Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 12, 2021, announces that STERIS plc (STERIS) has entered into a definitive Agreement and Plan of Merger to acquire Cantel Medical Corp. (Cantel). The transaction involves a complex series of mergers and conversions to integrate Cantel as a wholly-owned subsidiary of STERIS.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the acquisition rather than STERIS's operational financial results for a specific period.
- Merger Consideration: Cantel shareholders will receive $16.93 in cash and 0.33787 STERIS ordinary shares for each share of Cantel common stock held.
- Financing: STERIS has secured a bridge financing commitment from JPMorgan Chase Bank, N.A., for up to $2.1 billion in the form of a senior unsecured bridge facility.
- Termination Fee: If the agreement is terminated under specific conditions (e.g., failure to obtain stockholder approval, change in board recommendation, or acceptance of a superior proposal), Cantel must pay STERIS a fee of $127,400,000.
- Supporting Ownership: Key Cantel shareholders (Charles M. Diker, Mark N. Diker, and Diker Management LLC) have entered a Voting Agreement to vote approximately 10.37% of outstanding Cantel shares in favor of the merger.
Note: This filing does not provide STERIS's revenue, profit, cash flow, margins, or debt levels for the reporting period.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement. The consummation of the transaction is subject to several closing conditions, including:
- Approval by a majority of Cantel's outstanding shares.
- Approval for listing the STERIS shares to be issued on the New York Stock Exchange.
- Effectiveness of the Form S-4 registration statement.
- Receipt of requisite governmental and regulatory approvals, including Hart-Scott-Rodino Act approvals.
- Absence of legal orders prohibiting the transaction.
The transaction has an "Outside Date" of October 12, 2021, which may be extended to January 12, 2022, or April 12, 2022, if regulatory approvals are delayed.
Outlook, Risks, and Management Commentary
Management has issued a joint press release and investor presentation regarding the strategic rationale for the acquisition. The filing includes extensive forward-looking statements and risk factors, including:
- Regulatory Risk: Possibility that governmental entities may prohibit, delay, or refuse to grant necessary approvals.
- Integration Risk: Cost savings and synergies may not be fully realized or may take longer than expected; the transaction may not be accretive within the anticipated timeframe.
- Operational Disruption: Risks related to retaining key personnel, maintaining customer relationships, and business disruption during the transition.
- Market and Economic Risks: Impact of the COVID-19 pandemic, currency fluctuations, trade barriers, and changes in tax laws (including the Tax Cuts and Jobs Act).
- Legal Risk: Potential for shareholder litigation affecting the timing or occurrence of the transaction.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and Voting Agreement filed as Exhibits 2.1 and 10.1.
- Monitor the status of the Form S-4 registration statement and the upcoming Cantel stockholder vote.
- Review the investor presentation (Exhibit 99.2) for detailed synergy projections and strategic rationale.
- Track regulatory approval progress, specifically Hart-Scott-Rodino and other governmental clearances.
- Assess the impact of the $2.1 billion bridge facility on STERIS's future capital structure and liquidity.